Oruka Therapeutics Focuses on ORKA‑001 for Psoriasis as Phase 2 Data Approaches in 2026

Oruka Therapeutics (Nasdaq: ORKA), a clinical‑stage biotech company, is increasing investor and industry focus on its psoriasis drug candidate **ORKA‑001** as initial **Phase 2a EVERLAST‑A trial data is anticipated in the *second half of 2026***. ORKA‑001 is a long‑acting IL‑23p19 monoclonal antibody designed to treat moderate‑to‑severe plaque psoriasis with the potential for significantly **extended dosing intervals — possibly once or twice a year** — thanks to its extended pharmacokinetic profile. Interim Phase 1 results showed that ORKA‑001 demonstrated an approximately 100‑day half‑life, more than three times that of some current IL‑23 inhibitors, and a favorable safety profile in healthy volunteers, suggesting potential for deeper and longer‑lasting skin clearance with fewer doses. In parallel, Oruka’s broader pipeline includes ORKA‑002, an IL‑17A/F antibody in Phase 1 testing that could expand treatment into psoriatic arthritis and hidradenitis suppurativa. While ORKA‑001’s Phase 1 performance has sparked optimism, the investment thesis hinges on the EVERLAST‑A Phase 2a readout expected in late 2026 — a milestone that could validate the long‑acting biologic’s clinical advantages and influence Oruka’s market positioning. #OrukaTherapeutics #ORKA001 #PsoriasisTreatment #BiotechNews #SlimScan #GrowthStocks #CANSLIM